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was 2.1  1.6. Both NOAC and Watchman device were superior to
warfarin in hemorrhagic stroke prevention (OR¼0.46 [0.30-0.82] and
OR¼0.21 [0.05-0.99], respectively). NOAC also signiﬁcantly reduced
total stroke compared with warfarin (OR¼0.78 [0.58-0.96]) and
bleeding events (OR¼0.78 [0.65-0.91]). Indirect comparison between
NOAC and Watchman revealed no signiﬁcant differences in outcomes,
though there was a trend toward greater ischemic stroke with
Watchman compared with NOAC (OR 2.60 [0.60-13.96]) (Figure).
CONCLUSIONS NOAC therapy was superior to warfarin for multiple
outcomes while Watchman reduced hemorrhagic stroke. Further
studies are needed to assessWatchman for ischemic stroke prevention.
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BACKGROUND Cerebrovascular events can occur in up to 7% of pa-
tients following transcatheter aortic valve replacement (TAVR),
increasing dementia and mortality. Neuro-embolic events on post-
TAVR diffusion-weighted (DW) MRI are nearly universal, and have
been associated with cognitive decline. Embolic protection devices
(EPD) have not shown clinical reduction in post-TAVR neuro-embolic
events, but previous studies may have been under-powered to detect
signiﬁcant differences in outcomes.
METHODS We aimed to perform a meta-analysis evaluating EPD in
the prevention of clinical and imaging neuro-embolic events
following TAVR. Databases and conference abstracts were searched
for studies that compared efﬁcacy and safety outcomes of TAVR withand without EPD. Random-effects model was used. Heterogeneity
was examined with Cochran Q test and I2 statistics.
RESULTS A total of 4 studies with 289 patients were included, of
whom 152 (52.5%) underwent TAVR with an EPD. The success rate of
EPD implantation ranged from 89% to 100% (Table 1). In a follow-up
up to 30 days, the use of EPD in TAVR was associated with a
decreased incidence of new neurologic impairment identiﬁed by
specialist application of the National Institute of Health Stroke Scale
(OR 0.40; p¼0.04; Figure 1). EPDs were found to signiﬁcantly
increase ﬂuoroscopy time by a mean of 5.23 minutes (p<0.01). There
were no differences between groups in clinical strokes (p¼0.99),
disabling strokes (p¼0.70), DW-MRI lesions (p¼0.37), major vascular
complications (p¼0.85), life-threatening bleeding (p¼0.81), renal
insufﬁciency (p¼0.44), or mortality (p¼0.66).DesignTotal
population /
Embolic
protection Mean age Male DeviceValves,
number of
patientsProcedural
successCLEAN-TAVI
2014RCT 100 / 50 79 y 43% Claret
MontageCoreValve 94%DEFLECT III
2015RCT 85 / 46 82.4 y 46% TriGuard HDH SAPIEN, 54
CoreValve,
2689%PROTAVI-C
2014Prospective
cohort52 / 41 83 y 52% Embrella
Embolic
DeﬂectorSAPIEN 100%Samim 2015 Prospective
cohort52 / 15 84 y 53% Embrella
Embolic
DeﬂectorSAPIEN, 33
CoreValve,
1993%CONCLUSIONS This meta-analysis suggests that EPDs increase ﬂuo-
roscopy time in TAVR, but are otherwise safe, with a high technical
success rate. In addition, these devices have the potential to reduce
the incidence of TAVR-related new neurologic impairment. Thus, a
beneﬁt in the incidence of peri-procedural strokes may become
evident in larger clinical trials. Further studies are warranted to
conﬁrm these ﬁndings.
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BACKGROUND Intravenous thrombolytic therapy is the only FDA
approved treatment for large vessel anterior circulation acute
ischemic stroke (AIS). Previous evidence from randomized trials
evaluating the beneﬁt of endovascular therapy (EVT) for AIS have
shown conﬂicting results. The purpose of this meta-analysis was to
systematically examine clinical outcomes in randomized controlled
